CA 19-9, Cyfra 21-1, the ROMA score and HPV typing are the markers the upper programs add on top of the standard four. They narrow the questions the basic panel leaves open, and not one of them can find a cancer on its own.
CA 19-9 for the pancreas and bile ducts, Cyfra 21-1 for the lung, ROMA for ovarian risk, and HPV typing for cervical risk.
Medione A. Basic Health Checkup, where CA 19-9 sits in the same tumour-marker line as AFP and CEA. (≈$373)
Medione B-5. Precision - Respiratory Checkup, which names the lung-cancer marker on a line of its own. (≈$522)
Hanaro Gold, the cheapest programme carrying the ovarian-cancer risk score and the HPV test in one list. (≈$1,475)
One week is the earliest an imaging slot can be held, and there is no referral step before it.
English report in your hands in about a week. You also get a consultation on preliminary findings on the day of the screening, before you leave.
Programme contents and prices from each partner centre's own foreigner-facing published list, read 2026-08-05: KMI Global and Hanaro Medical Foundation's English site. Standalone per-test prices are a Korean partner centre's 비급여 (non-covered) posting, the itemised list 의료법 제45조 requires a clinic to publish, read the same day. Scheduling and report turnaround are Meridiko's own operating figures, confirmed 2026-08-06, not a centre's published ones (https://global.kmi.or.kr/examination/foreigner_examination; https://en-mobile.hanaromf.com/program/prog01/prog01_01.jsp), measured 2026-08-05. Dollar figures are converted from each centre's won price at ₩1,342 = $1 (open.er-api.com, 2026-09-13). The won figure is the price; the pairing moves with the rate.
CA 19-9 is used for pancreatic and biliary disease, Cyfra 21-1 for non-small-cell lung cancer, and the ROMA score combines CA-125 and HE4 into an ovarian-risk estimate that performs better than either alone. HPV typing identifies the viral strains that cause almost all cervical cancer, which is a genuine risk test rather than a marker.
Markers rise in benign disease and sit normal in early cancer. CA 19-9 in particular is raised by anything that obstructs bile, including gallstones. Used as a screening test in someone with no symptoms and no risk factors, a marker panel generates far more anxiety than findings.
Suits: People with a specific family history the marker matches, women wanting the stronger ovarian estimate rather than CA-125 alone, and anyone due for cervical screening who wants HPV typing with it rather than cytology alone.
Should not have it: Anyone treating a marker panel as a whole-body cancer check. That is what the imaging in these programs is for, and a normal marker set alongside no imaging is the least reassuring combination available.
The standard four markers in every entry program (AFP, CEA, CA-125 or PSA) cover the common ground. These four are targeted additions, and HPV typing is the odd one out: it is not a tumour marker at all but a test for the cause, which is why it has the clearest action attached.
Not itemised in every band this site prices. CA 19-9 sits in the tumour-marker line of every Medione programme except the MRI-only scan, and in both Hanaro programmes; Cyfra 21-1 in Medione's B-5. Precision - Respiratory Checkup and Hanaro's Gold; the ROMA score and HPV typing in Hanaro's Gold and Severance's Women's Health. Ask for the marker by name rather than assuming a band includes it.
